• Users Online: 249
  • Print this page
  • Email this page
Year : 2022  |  Volume : 26  |  Issue : 3  |  Page : 3-4

Successful use of dupilumab for treatment-resistant pityriasis amiantacea

Division of Dermatology, Dell Medical School, Austin, TX, USA

Correspondence Address:
Dr. Maya Firsowicz
Health Transformation Building, 1601 Trinity St Building A, Austin, TX 78712
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/jdds.jdds_109_20

Rights and Permissions

Pityriasis amiantacea (PA) is a scalp condition characterized by thick, adherent scales that are silvery or yellow–gray in color and bind down tufts of hair. PA is associated with several underlying dermatologic conditions including psoriasis, seborrheic dermatitis, atopic dermatitis, tinea capitis, pityriasis rosea, and Darier's disease. Although there is no consensus on standard treatment, PA is generally treated with keratolytic agents and/or ketoconazole shampoo. More resistant cases may require systemic therapies, including tumor necrosis factor-alpha inhibitors. We report a case of a 57-year-old female with severe PA resistant to numerous treatments including topical steroids, salicylic acid shampoo, intralesional steroid injections, mycophenolate mofetil, adalimumab, and apremilast. Following treatment with dupilumab, our patient experienced complete resolution of her PA. These results suggest that dupilumab may have in a role in the management of treatment-resistant PA, particularly when associated with eczematous dermatitis.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded65    
    Comments [Add]    

Recommend this journal